Pfizer: Smoking Cessation trials

The registry lists 44 Smoking Cessation studies with Pfizer as lead sponsor. 0 are open to participants now and 23 have results posted.

Phase 1 8Phase 2 6Phase 3 10Phase 4 11No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking CessationCompletedNCT02044874Phase 2Results posted
• Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.CompletedNCT01574703Phase 4Results posted
• Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric DisordersCompletedNCT01456936Phase 4Results posted
• A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through ReductionCompletedNCT01370356Phase 4Results posted
• Smoking Cessation Study In Healthy Adolescent SmokersCompletedNCT01312909Phase 4Results posted
• Varenicline Pregnancy Cohort StudyCompletedNCT01290445Results posted
• A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare ProviderCompletedNCT01244061Phase 4Results posted
• "VIBRATIONS" - A Study In Smokers Who Are Willing And Motivated To Stop Smoking With The Aid Of Varenicline Which Will Be Prescribed According To Usual Clinical Practice In GermanyCompletedNCT01104636Results posted
• Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With DepressionCompletedNCT01078298Phase 4Results posted
• Varenicline (Champix®) Special Investigation (Regulatory Post Marketing Commitment Plan)CompletedNCT01061710Results posted
• A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned SurgeryCompletedNCT00889720Phase 4Results posted
• Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To QuitCompletedNCT00818207Phase 4Results posted
• ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of SmokingCompletedNCT00808015Results posted
• Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino PatientsCompletedNCT00794365Results posted
• Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)CompletedNCT00772941Results posted
• Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or PlaceboCompletedNCT00749944Phase 4Results posted
• Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit DateCompletedNCT00691483Phase 4Results posted
• Varenicline Observational Investigation In The Cessation of SmokingCompletedNCT00669240Results posted
• Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00644969Phase 3Results posted
• Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop SmokingCompletedNCT00594204Phase 4Results posted
• Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® TabletsCompletedNCT00483002Results posted
• Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT00285012Phase 3Results posted
• Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit SmokingCompletedNCT00282984Phase 3Results posted
• A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.CompletedNCT01672645Phase 1
• Escape Smoke Project: Non-Intervention Non-Drug Multicenter Study on the Real-life Effectiveness of Smoking Cessation in General Practice in DenmarkCompletedNCT01544621
• A Study Evaluating the Absorption Of Varenicline Through The Skin Following Once Daily Application Of A Patch For 14 DaysCompletedNCT01234142Phase 1
• A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Patch Applied To The SkinCompletedNCT01013454Phase 1
• A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The SkinCompletedNCT00774605Phase 1
• A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking CessationWithdrawnNCT00741884Phase 2
• An Investigation Of The Effects Of Food On The Absorption Of A Varenicline Controlled Release FormulationCompletedNCT00731562Phase 1
• A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.CompletedNCT00661765Phase 1
• Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult SmokersCompletedNCT00527150Phase 1
• A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent SmokersCompletedNCT00463918Phase 1
• An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit SmokingCompletedNCT00371813Phase 3
• 12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.CompletedNCT00150254Phase 2
• A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking CessationCompletedNCT00150241Phase 2
• 12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking CessationCompletedNCT00150228Phase 2
• A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking CessationCompletedNCT00143364Phase 3
• An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking CessationCompletedNCT00143325Phase 3
• A 52-Week Placebo-Controlled Study Evaluating the Safety of VareniclineCompletedNCT00143299Phase 3
• A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking CessationCompletedNCT00143286Phase 3
• A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking CessationCompletedNCT00141206Phase 3
• A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking CessationCompletedNCT00141167Phase 3
• 12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking CessationCompletedNCT00139750Phase 2